Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561]

  • Discontinued
  • GID-TA10442
Following on from information provided to NICE by the company in March 2021, the appraisal of Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.